Ipamorelin Dosage in the Research: Doses, Routes & Half-Life
The gist
This page describes the ipamorelin doses used in studies, in animals and in the small number of human trials. It is not a how-to and contains no recommendation for any person. Every figure is third-person and tied to the study that used it.
The quick picture: in the human pharmacokinetics study, single intravenous doses ran from 4.21 to 140.45 nmol/kg [2]. In the one human efficacy trial, the dose was 0.03 mg/kg given intravenously twice daily [3]. In rats, bone-growth studies used 18 to 450 microg/day under the skin [4]; the 2024 ferret study used 1 to 3 mg/kg into the abdomen [5]. The drug clears quickly, with a terminal half-life of about 2 hours in humans, and produces one growth-hormone pulse peaking around 40 minutes after dosing [2]. Community "stack" protocols pairing it with CJC-1295 have no peer-reviewed human dosing basis and are not reproduced here as guidance.
Doses used in human studies
Human ipamorelin dosing exists in only two published contexts, and both are research settings. The pharmacokinetic study administered five 15-minute IV infusions at 4.21, 14.02, 42.13, 84.27, and 140.45 nmol/kg as single doses to map its kinetics [2]. The Phase 2 ileus trial administered 0.03 mg/kg intravenously twice daily on postoperative days 1 through 7 or until discharge [3]. Both were intravenous and clinician-administered. There is no validated human subcutaneous dose, no titration schedule, and no approved label, because ipamorelin is not an approved drug [3].
Doses used in animal studies
Rodent and ferret studies used a wider dose range across routes. The rat bone-growth study used 18, 90, and 450 microg/day subcutaneously, divided three times daily over 15 days [4]. A separate rat bone-mineral study used 0.5 mg/kg/day by continuous subcutaneous osmotic minipump over 12 weeks. Rat postoperative-ileus work used 0.1 to 1 mg/kg IV repeated four times daily. The 2024 ferret cachexia study used 1 to 3 mg/kg intraperitoneally [5]. These are species-specific experimental doses and do not translate to a human dose.
Half-life and routes studied
Ipamorelin clears quickly. Its terminal half-life is approximately 2 hours in healthy human volunteers (intravenous), with clearance of 0.078 L/h/kg and a steady-state volume of distribution of 0.22 L/kg [2]. The growth-hormone response is a single discrete pulse peaking around 40 minutes (0.67 h) after dosing [2]. Routes studied include intravenous (human PK and clinical trials; rodent efficacy), subcutaneous (rodent bone and body-composition studies, and the dominant route in community use), intranasal (rodent PK, around 20% bioavailability), and intraperitoneal (rodent and ferret efficacy) [5]. Ipamorelin itself is not orally bioavailable; only engineered ipamorelin-derived analogs show meaningful oral absorption.
How much cjc-1295 ipamorelin should i take
There is no evidence-based answer to how much cjc-1295 ipamorelin should i take, because no controlled human trial has tested the combination at any dose for any outcome [3]. The popular community subcutaneous "stack" protocols are not supported by peer-reviewed human pharmacokinetic or efficacy data and must be treated as anecdotal, not recommended [3]. What the literature does establish is single-agent pharmacology: ipamorelin's ~2-hour human half-life and single growth-hormone pulse [2], and CJC-1295's sustained GHRH-pathway activation and durable IGF-1 elevation [10]. This site does not provide a personal dose.
How to reconstitute cjc-1295 ipamorelin 5mg
On how to reconstitute cjc-1295 ipamorelin 5mg, the published literature offers only general peptide-handling observations, not a clinical preparation procedure. Ipamorelin is supplied as a lyophilized (freeze-dried) powder, free base or acetate salt, and is reconstituted with bacteriostatic water for research handling [2]. As a peptide it degrades with heat and repeated freeze-thaw, so reconstituted solution is typically kept refrigerated. These are research-supply handling notes, not preparation or dosing instructions for any person, and no approved formulation exists [3].